Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Read More
US regulators have placed on clinical hold three studies testing the immunotherapy Keytruda in combination with other therapies for multiple myeloma because of patient deaths.
Read More
Myeloma UK has launched a ground-breaking immunotherapy trial which aims to modulate the immune system to target myeloma.
Read More
The National Institute for Health and Care Excellence has published draft guidelines recommending ‘routine’ use of Celgene’s Imnovid on the NHS in England and Wales to treat some patients with multiple myeloma.
Read More
